WINT (Windtree Therapeutics Inc.) רווח למניה בארבעת הרבעונים האחרונים
Liquidity shortages and the risk of share dilution are putting pressure on Windtree Therapeutics (WINT). Reviewing the chart on GURU.Markets, we see that the current EPS YoY TTM growth rate of 73.30 reflects recent values. A diversified small-molecule portfolio reduces FDA regulatory barriers, yet the fierce competition for cardiology drug efficacy in this niche remains a serious challenge for the business.
פילוחי מדדים פיננסיים ומדדי שוק עבור Windtree (WINT)
Windtree Therapeutics focuses on developing bioengineered products for heart tissue regeneration. The EPS YoY TTM percentage trend reflects the annual growth rate of net income per share, recalculated based on the latest 10-Q reports. This indicator allows for tracking the actual business trajectory by excluding random fluctuations. Sharp peaks on the chart often reflect inflated market expectations, increasing the risk of a correction. Stable growth of this metric confirms the effectiveness of the company's R&D strategy.
